Connect with us


Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Moves Into A CAUMZTM Commercialization Deal With Alternavida



Tetra Bio Pharma Inc (OTCMKTS:TBPMF) today gave an update revealing its latest move with Alternavida S.A. de C.V.The two business giants got into definitive co-development and commercialization deal in line with a product known as CAUMZTM (PPP011). They will focus on the sale development, marketing, and distribution activities of this leading product.

Chamberland’s take

The CEO of Tetra Bio-Pharma, who is also its Chief Regulatory Officer, Dr. Guy Chamberland, has spoken in relation to the latest development. According to the leader, the opioid crisis is spreading at an astounding rate, and something needs to be done about the matter. It started from North America, and now it is finding its way into Mexico and other states.

Reports have placed the opioid epidemic at the top of the list when it comes to those conditions that require immediate attention. Scientists have termed the epidemic one of the biggest challenges the world is facing currently.

Chamberland is quite pleased with Alternavida and its dedication to opening up clinical sites to conduct trials for CAUMZTM.

Alternavida’s dedication to progress

Alternavida has been making strong efforts targeted at pushing for the approval of the drug. The aim has been to see the drug help the various suffering persons from around the globe.

The official adds that the business should be recognized for its lead role in the health and wellness sector.

Tetra Bio-Pharma has been quite vigilant, and so far, it has conducted discussions with several potential partners. However, it spotted Alternavida’s undying interest to work with it towards the development of CAUMZTM and marketing it.

Focus into the future

The business leader is optimistic that its relationship with the partner will be a meaningful one. It looks forward to co-operating with it as they seek to expand their reach within Mexico.

The terms of the deal are quite clear, with Alternavida expected to finance two trials in Mexico. Asides from that, it will undertake the registration exercise of the product in Mexico and see to its commercialization.

Tetra is looking forward to ramping up its efforts in the operation of its clinical sites in the US, Canada, and Mexico. It also seeks to expand its business to more territories.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.